Effects of TNF-alpha antagonism in patients with the metabolic syndrome and psoriasis

Journal of Drugs in Dermatology, Oct, 2007

Sponsors and Collaborators: Massachusetts General Hospital and Amgen. The purpose of this study is to determine how substances produced in the fat (inflammatory markers) relate to the risk of heart disease in people with the metabolic syndrome and psoriasis.

Condition           Intervention

Psoriasis           Drug: Etanercept (TNF-alpha antagonist)
Metabolic Syndrome
Hyperlipidemia
Obesity
Hypertension

Study ID Numbers: 2007-P-000494

ClinicalTrials.gov Identifier: NCT00477191

COPYRIGHT 2007 Journal of Drugs in Dermatology, Inc.
COPYRIGHT 2007 Gale Group

 

BNET TalkbackShare your ideas and expertise on this topic

Please add your comment:

  1. You are currently: a Guest |
  2.  

Basic HTML tags that work in comments are: bold (<b></b>), italic (<i></i>), underline (<u></u>), and hyperlink (<a href></a)

advertisement
advertisement
  • Click Here
  • Click Here
  • Click Here
advertisement

Content provided in partnership with Thompson Gale